Dongsung Pharm (002210) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dongsung Pharm (002210) has a cash flow conversion efficiency ratio of 0.104x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.20 Billion ≈ $2.85 Million USD) by net assets (₩40.55 Billion ≈ $27.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002210 net asset quality score to measure how much of total assets are equity-financed.
Dongsung Pharm - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Dongsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Dongsung Pharm's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Dongsung Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dongsung Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIORETEC OY
F:0TN
|
N/A |
|
Frtek Co.Ltd
KQ:073540
|
0.029x |
|
Nagarjuna Fertilizers and Chemicals Limited
NSE:NAGAFERT
|
0.074x |
|
Hsin-Sin Textile Co Ltd
TWO:4406
|
0.018x |
|
Arcure SA
PA:ALCUR
|
0.282x |
|
SBC Corp Bhd
KLSE:5207
|
-0.023x |
|
HM Inwest S.A.
WAR:HMI
|
0.164x |
|
Kiang Huat Sea Gull Trading Frozen Food Public Company Limited
BK:CHOTI
|
0.084x |
Annual Cash Flow Conversion Efficiency for Dongsung Pharm (2008–2024)
The table below shows the annual cash flow conversion efficiency of Dongsung Pharm from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Dongsung Pharm (002210) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩55.18 Billion ≈ $37.39 Million |
₩-9.94 Billion ≈ $-6.74 Million |
-0.180x | -67.06% |
| 2023-12-31 | ₩39.80 Billion ≈ $26.97 Million |
₩-4.29 Billion ≈ $-2.91 Million |
-0.108x | -18.93% |
| 2022-12-31 | ₩42.81 Billion ≈ $29.01 Million |
₩-3.88 Billion ≈ $-2.63 Million |
-0.091x | -53.08% |
| 2021-12-31 | ₩46.44 Billion ≈ $31.47 Million |
₩-2.75 Billion ≈ $-1.86 Million |
-0.059x | -164.99% |
| 2020-12-31 | ₩54.95 Billion ≈ $37.24 Million |
₩5.01 Billion ≈ $3.40 Million |
0.091x | +176.94% |
| 2019-12-31 | ₩70.10 Billion ≈ $47.50 Million |
₩-8.31 Billion ≈ $-5.63 Million |
-0.118x | -588.87% |
| 2018-12-31 | ₩57.48 Billion ≈ $38.96 Million |
₩1.39 Billion ≈ $944.20K |
0.024x | -13.40% |
| 2017-12-31 | ₩64.27 Billion ≈ $43.56 Million |
₩1.80 Billion ≈ $1.22 Million |
0.028x | +146.55% |
| 2016-12-31 | ₩55.62 Billion ≈ $37.69 Million |
₩-3.34 Billion ≈ $-2.27 Million |
-0.060x | -36.94% |
| 2011-12-31 | ₩60.20 Billion ≈ $40.80 Million |
₩-2.64 Billion ≈ $-1.79 Million |
-0.044x | -170.43% |
| 2010-12-31 | ₩59.10 Billion ≈ $40.05 Million |
₩3.68 Billion ≈ $2.50 Million |
0.062x | +184.40% |
| 2009-12-31 | ₩67.97 Billion ≈ $46.06 Million |
₩-5.02 Billion ≈ $-3.40 Million |
-0.074x | -1271.65% |
| 2008-12-31 | ₩67.82 Billion ≈ $45.96 Million |
₩-365.26 Million ≈ $-247.53K |
-0.005x | -- |
About Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more